Detection of necrotic malignant tissue and associated therapy

Details Detection of necrotic malignant tissue and associated therapy Detection of necrotic malignant tissue and associated therapy

1991-03-13

1999-03-16

Hollinden, Gary E.

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Attached to antibody or antibody fragment or immunoglobulin;...

424 111, 424 91, 5303871, A61K 5100, A61M 3614

Patent

active

058826262

ABSTRACT:
Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor. Also disclosed are antibodies for use with the foregoing methods.

REFERENCES:
patent: 4331647 (1982-05-01), Goldenberg
patent: 4361544 (1982-11-01), Goldenberg
patent: 4460559 (1984-07-01), Goldenberg
patent: 4460561 (1984-07-01), Goldenberg
patent: 4499183 (1985-02-01), Sujansky et al.
patent: 4613576 (1986-09-01), Cote et al.
patent: 4628027 (1986-12-01), Gay
patent: 4693966 (1987-09-01), Houghton et al.
patent: 4699877 (1987-10-01), Cline et al.
patent: 4735210 (1988-04-01), Goldenberg
patent: 4798790 (1989-01-01), Thomson et al.
patent: 4861581 (1989-08-01), Epstein et al.
patent: 5011920 (1991-04-01), Hakomori et al.
patent: 5019368 (1991-05-01), Epstein et al.
Epstein, A. and Clevenger, C. in Progress in Non-Histone Protein Research, Bekhor (Ed.), CRC Press, Boca Raton, 1985, pp. 117-137.
Clevenger, C. and Epstein, A. (1984), Exper. Cell Res. 151, 194-207.
Clevenger, C. and Epstein, A. (1984), J. of Histochem. and Cytochem, 32(7), 757-765.
Beller, G. et al., (1977), Circulation 55(1), 74-78.
Murao, S. et al., (1985), Cancer Res. 45, 791-795.
Bauer, K. et al., (1986), J of Histochem. and Cytochem. 34(2), 245-250.
Clevenger, C. et al., (1985), Cytometry 6, 208-214.
Bauer, K. et al., (1986), Cancer Res. 46, 2428-2434.
Chose, T. et al., (1975), Europ. J. Cancer 11, 321-326.
Pelham, J. et al., (1983), Cancer Immunol. Immunother. 15, 210-216.
Deguchi, T. et al., (1986), Cancer Res. 46, 3751-3755.
Hurwitz, E. et al., (1975), Cancer Res. 35, 1175-1181.
Marchalonis, J., (1969), Biochem. J. 113, 299-305.
Khaw, B. et al., (1976), J. Clin. Invest. 58, 439-446.
Khaw, B. et al., (1979), Circulation 60, 1527-1531.
Centocor: Product Brochure (SNM 1986), "Cardiac Patient Management".
Centocor: Product Brochure (SNM 1986), "Tumor Imaging with Monoclonal Antibodies: Ovarian and Breast CA."
Centocor: Product Brochure (SNM 1986), "Thrombus Detection with Monoclonal Antibodies."
Cooper et al., Cell Death in Normal and Malignant Tissues., Adv. Cancer Research, 21:59-120, 1975.
Khaw et al., Myocardial Damage Delineated by Indium-111 Antimyosin Fab and Technetium-99m Pyrophosphate, J. Nucl. Med. 28: 76-82 (1987).
Cater et al., Inflammatory Changes in Tumour Vessel After Systemic 5-Hydroxytryptamine, Bradykinin, Kallikrein, or Lysolecithin, Br., J. Cancer 20:517-525, 1966.
Thomlinson et al., The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy, Br. J. Cancer 9:539-549, 1955.
Morgan et al., Monoclonal Antibody Therapy of Cancer: Preclinical Models and Investigations in Humans, In: R. Herberman (ed.), Cancer Immunology: Innovative Approaches to Therapy, pp. 177-200, Boston, MA: Martinus Nijhoff Publishers, 1986.
G.G. Steel, "Cell Loss as a Factor in the Growth Rate of Human Tumours," pp. 381-387.
I.F. Tannock, "The Relations Between Cell Proliferation and the Vascular System in a Transplanted Mouse Mammary Tumour," pp. 258-272.
E.H. Cooper, "The Biology of Cell Death in Tumours." Cell Tissue Kinet., pp. 87-95, (1973).
T.G. Fulghum et al., Clinical Research, vol. 31, No. 2, p. 459A (1983).
A.M. Keenan et al., J. Nuclear Medicine, vol. 26, No. 5, 531-537 (May 1985).
Khaw, et al., Science 209: 295-297 (1980).
Chem. Abstracts 107(7):57118b, 1987 S. Welt et al., "Monoclonal Antibody to an Intracellular Antigen" PNA's 84(12), 4200-4.
Carbonari et al., "Detection & Characterization of Apoptotic Peripheral Blood Lymphocytes . . . ," Blood vol. 83(5), Mar. 1, 1994, pp. 1268-1277.
Curnow et al., "The Role of Apoptosis . . . ," Cancer Immunol. Immunother. vol. 36, 1993, pp. 149-155.
Laster et al., "Tumor Necrosis Factor . . . ," J. Immunol., vol. 141(8), Oct. 15, 1988, pp. 2629-2634.
Epstein et al., "Radioimmunodetection of Necrotic Lesions . . . ," Antibody, Immunoconjugates, & Radiopharmaceuticals. vol. 4(2), 1991, pp. 151-161.

Affiliated with

Also associated with

Rating

Detection of necrotic malignant tissue and associated therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Detection of necrotic malignant tissue and associated therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection of necrotic malignant tissue and associated therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-814661